You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

980 Results
Regimen
Regimen
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
Mar 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Oct 2017
Regimen
Cancer Type:
Gastrointestinal, 
Small bowel and appendix
Intent: Neoadjuvant
Funding:
ODB - General Benefit
    capecitabine
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Neoadjuvant
Funding:
ODB - General Benefit
    capecitabine
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine

Pages